Fennec Pharmaceuticals


This biotechnology company focused on the development of Sodium Thiosulfate for the prevention of ototoxicity
Fennec Pharmaceuticals is a not big biotechnology company aimed at the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. Unfortunately, platinum-based therapies cause ototoxicity in many patients, and are particularly harmful to the survivors of pediatric cancer.
Nowadays, STS is being studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity.
Business Type: Nanotextile » | Biotechnology » | Electrotechnics » |
Fennec PharmaceuticalsFennec Pharma PO Box 13628 68 TW Alexander Drive Research Triangle Park, |
Share with friends:
Next companies in category
Nanotechnology in medicine | Nano materials | Nanotechnology electronics | Nano asociation |
Follow Nanotechnology Journal on
© 2008 - 2025 Nanotechnology research | All rights reserved | Developed by Makovic.net